Gene Therapy by Targeted Adenovirus-mediated Knockdown of Pulmonary Endothelial Tph1 Attenuates Hypoxia-induced Pulmonary Hypertension

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2012 Apr 25

PMID 22525513

Citations 27

Authors

Ian Morecroft

Katie White

Paola Caruso

Margaret Nilsen

Lynn Loughlin

Raul Alba

Paul N Reynolds

Sergei M Danilov

Andrew H Baker

Margaret R MacLean

Affiliations

Soon will be listed here.

Abstract

Serotonin is produced by pulmonary arterial endothelial cells (PAEC) via tryptophan hydroxylase-1 (Tph1). Pathologically, serotonin acts on underlying pulmonary arterial cells, contributing to vascular remodeling associated with pulmonary arterial hypertension (PAH). The effects of hypoxia on PAEC-Tph1 activity are unknown. We investigated the potential of a gene therapy approach to PAH using selective inhibition of PAEC-Tph1 in vivo in a hypoxic model of PAH. We exposed cultured bovine pulmonary arterial smooth muscle cells (bPASMCs) to conditioned media from human PAECs (hPAECs) before and after hypoxic exposure. Serotonin levels were increased in hypoxic PAEC media. Conditioned media evoked bPASMC proliferation, which was greater with hypoxic PAEC media, via a serotonin-dependent mechanism. In vivo, adenoviral vectors targeted to PAECs (utilizing bispecific antibody to angiotensin-converting enzyme (ACE) as the selective targeting system) were used to deliver small hairpin Tph1 RNA sequences in rats. Hypoxic rats developed PAH and increased lung Tph1. PAEC-Tph1 expression and development of PAH were attenuated by our PAEC-Tph1 gene knockdown strategy. These results demonstrate that hypoxia induces Tph1 activity and selective knockdown of PAEC-Tph1 attenuates hypoxia-induced PAH in rats. Further investigation of pulmonary endothelial-specific Tph1 inhibition via gene interventions is warranted.

Citing Articles

Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease.

Katz M, Ohad D, Putter P, Shtraizent N, Shahar E, Tal S Front Vet Sci. 2024; 11:1415030.

PMID: 39376911 PMC: 11457017. DOI: 10.3389/fvets.2024.1415030.

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression.

Legchenko E, Chouvarine P, Qadri F, Specker E, Nazare M, Wesolowski R JACC Basic Transl Sci. 2024; 9(7):890-902.

PMID: 39170954 PMC: 11334415. DOI: 10.1016/j.jacbts.2024.04.006.

5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function.

Walker M, Bloodworth J, Kountz T, McCarty S, Green J, Ferrie R Front Allergy. 2024; 5:1385168.

PMID: 38845678 PMC: 11153829. DOI: 10.3389/falgy.2024.1385168.

Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics.

Ba H, Guo Y, Jiang Y, Li Y, Dai X, Liu Y Respir Res. 2024; 25(1):221.

PMID: 38807129 PMC: 11131231. DOI: 10.1186/s12931-024-02775-5.

Advanced approaches to overcome biological barriers in respiratory and systemic routes of administration for enhanced nucleic acid delivery to the lung.

Kwak G, Lee D, Suk J Expert Opin Drug Deliv. 2023; 20(11):1531-1552.

PMID: 37946533 PMC: 10872418. DOI: 10.1080/17425247.2023.2282535.

References

Alba R, Bradshaw A, Coughlan L, Denby L, McDonald R, Waddington S . Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood. 2010; 116(15):2656-64. PMC: 2974579. DOI: 10.1182/blood-2009-12-260026. View

Chin A, Svejda B, Gustafsson B, Granlund A, Sandvik A, Timberlake A . The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion. Am J Physiol Gastrointest Liver Physiol. 2011; 302(3):G397-405. PMC: 3287403. DOI: 10.1152/ajpgi.00087.2011. View

Izikki M, Hanoun N, Marcos E, Savale L, Barlier-Mur A, Saurini F . Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2007; 293(4):L1045-52. DOI: 10.1152/ajplung.00082.2007. View

Sakowski S, Geddes T, Thomas D, Levi E, Hatfield J, Kuhn D . Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res. 2006; 1085(1):11-8. DOI: 10.1016/j.brainres.2006.02.047. View

Hickman A, Klein D, Dyda F . Melatonin biosynthesis: the structure of serotonin N-acetyltransferase at 2.5 A resolution suggests a catalytic mechanism. Mol Cell. 1999; 3(1):23-32. DOI: 10.1016/s1097-2765(00)80171-9. View

Lane K, Machado R, Pauciulo M, Thomson J, Phillips 3rd J, Loyd J . Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000; 26(1):81-4. DOI: 10.1038/79226. View

White K, Dempsie Y, Nilsen M, Wright A, Loughlin L, MacLean M . The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2010; 90(2):373-82. DOI: 10.1093/cvr/cvq408. View

Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G . Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004; 94(9):1263-70. DOI: 10.1161/01.RES.0000126847.27660.69. View

Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, Dempsie Y . In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res. 2009; 85(3):593-603. DOI: 10.1093/cvr/cvp306. View

10.

Li N, Wallen N, Ladjevardi M, Hjemdahl P . Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis. 1998; 8(8):517-23. DOI: 10.1097/00001721-199711000-00006. View

11.

Ni W, Geddes T, Priestley J, Szasz T, Kuhn D, Watts S . The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol. 2008; 154(3):663-74. PMC: 2439511. DOI: 10.1038/bjp.2008.111. View

12.

Villalon C, Centurion D . Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(1-2):45-63. DOI: 10.1007/s00210-007-0179-1. View

13.

Kawut S, Horn E, Berekashvili K, Lederer D, Widlitz A, Rosenzweig E . Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006; 19(5):370-4. DOI: 10.1016/j.pupt.2006.01.001. View

14.

Camilleri M . LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010; 13(12):921-8. View

15.

Iida Y, Sawabe K, Kojima M, Oguro K, Nakanishi N, Hasegawa H . Proteasome-driven turnover of tryptophan hydroxylase is triggered by phosphorylation in RBL2H3 cells, a serotonin producing mast cell line. Eur J Biochem. 2002; 269(19):4780-8. DOI: 10.1046/j.1432-1033.2002.03188.x. View

16.

Orte C, Polak J, Haworth S, Yacoub M, Morrell N . Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol. 2000; 192(3):379-84. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q. View

17.

Fishman A . Hypoxia on the pulmonary circulation. How and where it acts. Circ Res. 1976; 38(4):221-31. DOI: 10.1161/01.res.38.4.221. View

18.

Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D . Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005; 111(21):2812-9. DOI: 10.1161/CIRCULATIONAHA.104.524926. View

19.

Balyasnikova I, Yeomans D, McDonald T, Danilov S . Antibody-mediated lung endothelium targeting: in vivo model on primates. Gene Ther. 2002; 9(4):282-90. DOI: 10.1038/sj.gt.3301657. View

20.

Lee S, Wang W, Moore B, Fanburg B . Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ Res. 1991; 68(5):1362-8. DOI: 10.1161/01.res.68.5.1362. View